Date: 2011-05-09
Type of information: R&D agreement
Compound:
Company: Kancera (Sweden) Professor Mary Hendrix and her research group at The Robert H. Lurie Comprehensive Cancer Center (USA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: In line with Kancera’s strategy for the development of new therapies towards cancer, the company enters collaboration with Professor Mary Hendrix and her research group at The Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine, Chicago USA. Under the collaboration, Professor Hendrix and Kancera combine strengths in disease mechanism R&D and product development to deliver novel therapies aimed at overcoming drug resistance and relapse in cancer. Professor Hendrix’s team will joint forces with Kancera AB to develop more effective cancer treatments and to establish early prognostic markers of cancer development and drug resistance.
Financial terms: Financial details were not disclosed.
Latest news:
